1,205 research outputs found
Dr. Gerd J. Horten Professor of History - Concordia University Portland
No full textGerd Horten, author of the book \u27Radio Goes to War: The Cultural Politics of Propaganda during World War II\u27, discusses World War II propaganda and censorship. Recorded by Phil Sedgwick.
Video uploaded by Phil Sedgwick under Standard YouTube Licensehttps://commons.cu-portland.edu/humfacultymedia/1000/thumbnail.jp
Endogenous Fixprices and Sticky Price Adjustment of Risk-averse Firms
No full textA risk-averse price-setting firm which knows the quantity demanded at the status quo price but has imperfect information otherwise may choose not to change it although an otherwise identical risk-neutral firm would do so, provided the variance of the firm's subjective probability distribution over quantities demanded as a function of price displays a kink at the status quo. This is equivalent to risk aversion of order one. When no such endogenous fixprice exists, the size of price adjustment still tends to zero as risk aversion tends to infinity, and to any arbitrarily small menu cost there exists a degree of risk aversion so that the firm will not adjust.fixed prices, price adjustment, risk aversion, menu cost
New glucocorticoids on the horizon: Repress, don't activate!
No full textGlucocorticoids are highly effective drugs; their immunosuppressive and antiinflammatory actions are used in the treatment of many rheumatic and other inflammatory diseases. However, their use is sometimes considerably limited by numerous adverse reactions. For this reason, great efforts have been made in recent years to develop innovative glucocorticoids or glucocorticoid receptor ligands that have improved therapeutic effect/adverse reaction ratio. We summarize the position and critically discuss the following products that are currently under development: (1) selective glucocorticoid receptor agonists (SEGRA or dissociating glucocorticoids); (2) nitrosteroids; and (3) long-circulating liposomal glucocorticoids. Finally, we describe the state of research on membrane-bound glucocorticoid receptors as possible further targets for specific glucocorticoid actions
New glucocorticoids on the horizon: Repress, don't activate!
No full textGlucocorticoids are highly effective drugs; their immunosuppressive and antiinflammatory actions are used in the treatment of many rheumatic and other inflammatory diseases. However, their use is sometimes considerably limited by numerous adverse reactions. For this reason, great efforts have been made in recent years to develop innovative glucocorticoids or glucocorticoid receptor ligands that have improved therapeutic effect/adverse reaction ratio. We summarize the position and critically discuss the following products that are currently under development: (1) selective glucocorticoid receptor agonists (SEGRA or dissociating glucocorticoids); (2) nitrosteroids; and (3) long-circulating liposomal glucocorticoids. Finally, we describe the state of research on membrane-bound glucocorticoid receptors as possible further targets for specific glucocorticoid actions
Comparison of contrast-enhanced ulthasunography (CE-US) and MR-imaging (CE-MRI) in monitoring the efficacy of a bradykinin receptor-2 antagonist in painful knee osteoarthritis (OA)
No full textComparison of contrast-enhanced ulthasunography (CE-US) and MR-imaging (CE-MRI) in monitoring the efficacy of a bradykinin receptor-2 antagonist in painful knee osteoarthritis (OA)
No full textTreating gastro-oesophageal reflux disease (GERD) with sense
No full textGastro-esophageal reflux disease (GERD) is a common disorder that affects an estimated 5 % to 7 % of the global population. Management of GERD often poses a number of challenges. In this article, the author presents a number of management modalities for this condition.peer-reviewe
- …
